Targeting JNK for therapeutic depletion of stem-like glioblastoma cells

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Matsuda, Ken Ichiro ^a   Sato, Atsushi ^a   Okada, Masashi ^a   Shibuya, Keita ^a   Seino, Shizuka ^a   Suzuki, Kaori ^a,b   Watanabe, Eriko ^a   Narita, Yoshitaka ^b   Shibui, Soichiro ^b   Kayama, Takamasa ^a   Kitanaka, Chifumi ^a,c,d  

^a YAMAGATA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL; ARTICLE; BRAIN TUMOR; CANCER STEM CELL; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GLIOBLASTOMA; HUMAN; MALE; MORTALITY; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864132864     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00516     Document Type: Article

References (47)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996 (2005). (Pubitemid 40349501)
2. Cheng, L., Bao, S. & Rich, J. N. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80, 654-665 (2010).
3. Lathia, J. D., Venere, M., Rao, M. S. & Rich, J. N. Seeing is believing: Are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev 7, 227-237 (2011).
4. Neman, J. & Jandial, R. Decreasing glioma recurrence through adjuvant cancer stem cell inhibition. Biologics 4, 157-162 (2010).
5. Tabatabai, G. & Weller, M. Glioblastoma stem cells. Cell Tissue Res 343, 459-465 (2011).
6. Grossman, S. A. & Batara, J. F. Current management of glioblastoma multiforme. Semin Oncol 31, 635-644 (2004). (Pubitemid 39389014)
7. Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N Engl J Med 359, 492-507 (2008).
8. Mangiola, A. et al.Glioblastoma therapy: going beyond Hercules Columns. Expert Rev Neurother 10, 507-514 (2010).
9. Papadopoulos, M. C., Saadoun, S., Davies, D. C. & Bell, B. A. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 15, 101-108 (2001). (Pubitemid 32423258)
10. Sanai, N., Alvarez-Buylla, A. & Berger, M. S. Neural stem cells and the origin of gliomas. N Engl J Med 353, 811-822 (2005).
11. Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710 (2007). (Pubitemid 350070717)
12. Muldoon, L. L. et al. Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 25, 2295-2305 (2007). (Pubitemid 46954658)
13. Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008).
14. Clevers, H. The cancer stem cell: premises, promises and challenges. NatMed 17, 313-319 (2011).
15. Stiles, C. D. & Rowitch,D.H.Glioma stem cells: Amidterm exam. Neuron 58, 832-846 (2008). (Pubitemid 351842757)
16. Gutkind, J. S. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE 2000, re1 (2000).
17. Bennett, B. L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98, 13681-13686 (2001). (Pubitemid 33115958)
18. Zhang, D., Song, L., Li, J., Wu, K. & Huang, C. Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses. J Biol Chem 281, 34113-34123 (2006). (Pubitemid 46036620)
19. Sunayama, J. et al. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 29, 1327-1337 (2011).
20. Gross, N. D. et al. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. Clin Cancer Res 13, 5910-5917 (2007). (Pubitemid 47583919)
21. Beier, D. et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68, 5706-5715 (2008).
22. Wang, W. et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 48, 195-202 (2004). (Pubitemid 38096401)
23. Morgan, L. et al. Development of a pentylenetetrazole-induced seizure model to evaluate kinase inhibitor efficacy in the central nervous system. Neurosci Lett 395, 143-148 (2006). (Pubitemid 43188881)
24. Wang, Y. et al. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. J Neurol Sci 285, 172-177 (2009).
25. Sharma, N., Deshmukh, R. & Bedi, K. L. SP600125, a competitive inhibitor of JNK attenuates streptozotocin induced neurocognitive deficit and oxidative stress in rats. Pharmacol Biochem Behav 96, 386-394 (2010).
26. Ramin, M., Azizi, P.,Motamedi, F., Haghparast, A. & Khodagholi, F. Inhibition of JNK phosphorylation reverses memory deficit induced by beta-amyloid (1-42) associated with decrease of apoptotic factors. Behav Brain Res 217, 424-431 (2011).
27. Antonyak, M. A. et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21, 5038-5046 (2002).
28. Assimakopoulou, M., Kondyli, M., Gatzounis, G., Maraziotis, T. & Varakis, J. Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. BMC Cancer 7, 202 (2007).
29. Li, J. Y. et al. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 88, 11-17 (2008).
30. Cui, J. et al. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 66, 10024-10031 (2006). (Pubitemid 44672055)
31. Vivanco, I. et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11, 555-569 (2007). (Pubitemid 46856910)
32. Rong, Y. et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 69, 2540-2549 (2009).
33. Rasheed, Z. A., Kowalski, J., Smith, B. D. & Matsui, W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883-887 (2011).
34. Yoon, C. H. et al. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene, doi:10.1038/ onc.2011.634 (2012).
35. Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4, 568-580 (2009).
36. Fael Al-Mayhani, T. M. et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 176, 192-199 (2009).
37. Sunayama, J. et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28, 1930-1939 (2010).
38. Ikushima, H. et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5, 504-514 (2009).
39. Sunayama, J. et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 12, 1205-1219 (2010).
40. Sato, A. et al. MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis. Stem Cells 29, 1942-1951 (2011).
41. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
42. Chen, R. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17, 362-375 (2010).
43. Lalonde, R. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26, 91-104 (2002). (Pubitemid 34130537)
44. Hughes, R. N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 28, 497-505 (2004). (Pubitemid 39311449)
45. Reisel, D. et al. Spatial memory dissociations inmice lacking GluR1. Nat Neurosci 5, 868-873 (2002). (Pubitemid 34976652)
46. Washida, K. et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 41, 1798-1806 (2010).
47. Shinzawa, K. & Tsujimoto, Y. PLA2 activity is required for nuclear shrinkage in caspase-independent cell death. J Cell Biol 163, 1219-1230 (2003). (Pubitemid 38032084)